Frontiers in Oncology | |
SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study | |
Oncology | |
Carolyn A. Michaels1  William L. Greene1  Elizabeth G. Swift1  Anita Max1  Diego R. Hijano2  Jose A. Ferrolino2  Ronald H. Dallas2  Hana Hakim2  Joshua Wolf3  Ted H. Morton4  Randall T. Hayden5  Shane J. Cross6  Julie L. Richardson6  | |
[1] Center for Advanced Practice Providers, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, United States;Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pathology, St. Jude Children Research Hospital, Memphis, TN, United States;Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children Research Hospital, Memphis, TN, United States; | |
关键词: coronavirus; immunocompromised; cancer; hematopoietic cell transplant; monoclonal antibodies; | |
DOI : 10.3389/fonc.2023.1229655 | |
received in 2023-05-26, accepted in 2023-07-10, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28–135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.
【 授权许可】
Unknown
Copyright © 2023 Hijano, Ferrolino, Swift, Michaels, Max, Hayden, Wolf, Dallas, Greene, Richardson, Hakim, Morton and Cross
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310104882846ZK.pdf | 442KB | download |